Biogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 200 Milligram Dose
September 16 2021 - 8:20AM
Dow Jones News
By Dave Sebastian
Biogen Inc. said its Phase 2 study of vixotrigine, a drug being
evaluated for the treatment of small fiber neuropathy, met its
primary endpoint for the 200 milligram, twice-daily dose.
The study for the higher dose of 350 milligrams, twice daily
didn't meet the primary endpoint, the company said Thursday, but it
met the statistical significance in the patient global impression
of change at week 12.
Small fiber neuropathy involves severe pain that begins in the
feet or hands. Both doses were generally well tolerated by
participants, the company said.
Write to Dave Sebastian at dave.sebastian@wsj.com
(END) Dow Jones Newswires
September 16, 2021 08:05 ET (12:05 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2023 to Apr 2024
